ATE488238T1 - Verwendung von thiazolbenzo-heterocyclenfür die behandlung von multipler sklerose - Google Patents

Verwendung von thiazolbenzo-heterocyclenfür die behandlung von multipler sklerose

Info

Publication number
ATE488238T1
ATE488238T1 AT03814050T AT03814050T ATE488238T1 AT E488238 T1 ATE488238 T1 AT E488238T1 AT 03814050 T AT03814050 T AT 03814050T AT 03814050 T AT03814050 T AT 03814050T AT E488238 T1 ATE488238 T1 AT E488238T1
Authority
AT
Austria
Prior art keywords
multiple sclerosis
thiazolbenzo
heterocycles
treatment
inflammatory
Prior art date
Application number
AT03814050T
Other languages
English (en)
Inventor
Bin Zhu
Joseph Wettstein
Margaret Petty
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE488238T1 publication Critical patent/ATE488238T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03814050T 2002-12-17 2003-12-16 Verwendung von thiazolbenzo-heterocyclenfür die behandlung von multipler sklerose ATE488238T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43400302P 2002-12-17 2002-12-17
PCT/US2003/040078 WO2004058271A1 (en) 2002-12-17 2003-12-16 Use of thiazolobenzoheterocycles for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
ATE488238T1 true ATE488238T1 (de) 2010-12-15

Family

ID=23722415

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03814050T ATE488238T1 (de) 2002-12-17 2003-12-16 Verwendung von thiazolbenzo-heterocyclenfür die behandlung von multipler sklerose

Country Status (10)

Country Link
US (1) US7041661B2 (de)
EP (1) EP1585525B1 (de)
AT (1) ATE488238T1 (de)
AU (1) AU2003300976A1 (de)
BR (1) BR0317413A (de)
CA (1) CA2508222A1 (de)
DE (1) DE60335029D1 (de)
GB (1) GB0307067D0 (de)
MX (1) MXPA05006296A (de)
WO (1) WO2004058271A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010031054A1 (en) 2008-09-15 2010-03-18 Biovista, Inc. Compositions and methods for treating epilepsy
WO2013130422A1 (en) 2012-02-27 2013-09-06 Biovista, Inc. Compositions and methods for treating mitochondrial diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2649701B2 (fr) * 1988-12-15 1991-11-22 Rhone Poulenc Sante Derives d'imino-2 benzothiazoline, leurs procedes de preparation et les medicaments les contenant
FR2766487B1 (fr) * 1997-07-28 1999-08-27 Rhone Poulenc Rorer Sa Thiazolobenzoheterocycles, leur preparation et les medicaments les contenant
FR2826004B1 (fr) 2001-06-13 2008-03-28 Aventis Pharma Sa Procede de preparation de derives estrogenes

Also Published As

Publication number Publication date
EP1585525A1 (de) 2005-10-19
BR0317413A (pt) 2005-11-08
MXPA05006296A (es) 2005-08-29
GB0307067D0 (en) 2003-04-30
DE60335029D1 (de) 2010-12-30
WO2004058271A1 (en) 2004-07-15
US7041661B2 (en) 2006-05-09
CA2508222A1 (en) 2004-07-15
US20040147504A1 (en) 2004-07-29
AU2003300976A1 (en) 2004-07-22
EP1585525B1 (de) 2010-11-17

Similar Documents

Publication Publication Date Title
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
IS8058A (is) Sýklísk súlfónamíð til að hamla gamma seytiasa
DE60224879D1 (de) Verwendung von dpiv-inhibitoren als therapeutika für krankhafte neurologische zustände
ATE464323T1 (de) Zusammensetzungen und verfahren für die tumor- diagnose und behandlung
ATE414697T1 (de) Nf-kb-inhibitoren
ATE539751T1 (de) Verwendung von brimonidine zur behandlung von stress assoziierten zuständen
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
DE60231050D1 (de) Verwendung von Totarol zur Behandlung von Pruritus
ECSP024244A (es) Uso de (z)-2-cyano-3-hydroxy-but-2-enoic acid(4´-trifluoromethylphenyl)-amide para el tratamiento de la esclerosis múltiple
ATE323084T1 (de) Für die behandlung von alzheimer krankheit geeignete makrocyclen
DE60220385D1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
ATE494296T1 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
DE602005020263D1 (de) Für die behandlung von entzündlichen krankheiten nützliche beta-carboline
ECSP055844A (es) Nuevos compuestos triciclicos
ATE443044T1 (de) Tace inhibitoren
ATE512147T1 (de) Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer
ATE346040T1 (de) Aryl-sulfonamide als serotonin-antagonisten für de behandlung von fettleibigkeit
DE60335029D1 (de) Verwendung von thiazolbenzo-heterocyclenfür die behandlung von multipler sklerose
ATE423102T1 (de) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer
ATE453386T1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
ATE358673T1 (de) Nf-kb-inhibitoren
TW200600084A (en) Anti-coronavirus compounds
ATE534380T1 (de) Glepp-1-hemmer bei der behandlung von autoimmun- und/oder entzündungskrankheiten
NO20033541L (no) Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties